February 5, 2018

Tosk has been awarded a $2 million grant from National Cancer Institute to continue the company’s TK-kRAS research program.

The National Cancer Institute (NCI) has awarded Tosk a two-year, $2 million grant to continue its highly promising oncologic kRAS research program. The kRAS project is […]
February 5, 2018

Tosk has had excellent though preliminary results of its recently inaugurated human trials for its TK-90 drug, which protects again mucositis.

Tosk has initiated human trials for its TK-90 drug, and preliminary results are encouraging. The drug is intended to reduce or eliminate the side effects of […]
February 5, 2018

Preclinical efficiency testing in a rat model of doxorubicin-induced cardiotoxicity reduction has demonstrated statistically significant protection.

TK-39, Tosk’s second patented product, which blocks damage to the heart (cardiotoxicity) resulting from widely used cancer drugs known as anthracyclines, has proved preclinical efficacy testing […]
February 5, 2018

Tosk CEO Brian Frenzel meets with potential distribution partners and investors.

Brian Frenzel, CEO and co-founder of Tosk, recently returned from China , where he met potential distribution partners and investors. “China obviously will be a key […]